Osteoporosis is a chronic bone disease whose prevalence increases with age. It results from an alteration in the quantity and quality of the skeleton (micro-architecture and bone mineral density) with an increased risk of fracture and co-morbidities. According to recent epidemiological studies, it is estimated that this pathology affects around 30% of people over 50 years of age in Europe, resulting in an excess mortality rate of almost 30%, and in an annual socio-economic cost of nearly 30 billion euros. Current treatment is limited by non-systematic prophylaxis and the side effects of curative treatments, with compliance rates of no more than 20% within one year. To meet these challenges, new innovative preventive nutrition alternatives based on the combined use of active food ingredients are more necessary than ever. Fisetin is a polyphenol of the flavonoid class described for its anti-inflammatory activity. It is mainly found in red fruits such as strawberries. We have previously demonstrated how and to what extent fisetin inhibits osteoclast differentiation, stimulates osteoblast activity, and prevents bone loss in murine osteoporotic models. In order to optimize this beneficial effect, we have sought nutritional partners who could act in synergy with fistin. We have shown that DHA, an omega-3 polyunsaturated fatty acid, can potentiate the biological effects of fisetin at the bone level. Our work has made it possible to highlight the form of DHA and the most relevant combination ratios. Collaborative work in partnership has made it possible to develop formulations and extracts on the basis of the research results. The long-term objective is to transpose this work to patients, in order to provide marketable and scientifically supported prevention tools.